Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 236

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 236
---
   |
| Cash paid for financing costs in connection with SEPA                                    |   |                      (25,000 | ) |   |          - |   |
| Net cash provided by financing activities                                                |   |                    3,759,101 |   |   |          - |   |
| Net decrease in cash and cash equivalents during the period                              |   |                     (181,893 | ) |   | (1,176,933 | ) |
| Cash and cash equivalents, beginning of the year                                         |   |                    4,164,323 |   |   |  1,719,338 |   |
| Cash and cash equivalents, end of the year                                               | $ |                    3,982,430 |   | $ |    542,405 |   |
| Supplemental disclosure of non-cash investing and financing activities                   |   |                              |   |   |            |   |
| Right-of-use assets obtained in exchange for lease liabilities                           | $ |                            - |   | $ |    356,805 |   |
| Receivable for proceeds of warrant exercises                                             | $ |                       14,000 |   | $ |          - |   |
| Issuance costs included in accounts payable                                              | $ |                       95,120 |   | $ |          - |   |
| Deferred issuance costs on issued shares related to SEPA agreement                       | $ |                      300,000 |   | $ |            |   |

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

<div align='center'>F-28

MEDICUS PHARMA LTD.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)</div>

1. Description of business

Medicus Pharma Ltd. (the "Company" or "Medicus Pharma"), formerly Interactive Capital Partners Corporation ("Interactive"), is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

The Company is a public limited Company originally incorporated pursuant to the provisions of the Business Corporations Act (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities. The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada.

Liquidity and Going Concern

The Company has incurred